Indeed, the SRC inhibitors dasatinib and bosutinib have been approved for clinical usage in the treatment of chronic myeloid leukemia [52,53], and KX2-391 has been approved for the treatment of actinic keratosis and for the prevention of the development of actinic keratosis into squamous cell carcinoma [54]. The gene discussed is SRC; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.